The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shin Nippon Biomedical Laboratories's Revenue for the
three
months ended in Mar. 2026 was $71.4 Mil. Shin Nippon Biomedical Laboratories's average Accounts Receivable for the
three
months ended in Mar. 2026 was $39.3 Mil.
Hence, Shin Nippon Biomedical Laboratories's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.82.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shin Nippon Biomedical Laboratories Receivables Turnover Related Terms
Shin Nippon Biomedical Laboratories Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBLOF vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Receivables Turnover of 1.82 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shin Nippon Biomedical Laboratories and its competitors. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #107 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 53%.
Is Shin Nippon Biomedical Laboratories' Receivables Turnover too high?
Shin Nippon Biomedical Laboratories' current Receivables Turnover is 1.82. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Shin Nippon Biomedical Laboratories' value of 1.82 is 66.3% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #107 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #107 out of 202 companies for Receivables Turnover. This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median Receivables Turnover is 5.40. Shin Nippon Biomedical Laboratories' value of 1.82 is 66.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Receivables Turnover of 1.82 is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Receivables Turnover is 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Receivables Turnover of 1.82. The stock's GF Value™ is $13.86, compared to a current price of $9.16 — trading 33.9% below its estimated fair value. The current Receivables Turnover is 1.82 and 66.3% below the Medical Diagnostics & Research industry median of 5.40. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Receivables Turnover is 1.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 33.9% below its estimated GF Value™ of $13.86.
Key valuation signals for SBLOF:
Receivables Turnover: 1.82
GF Value™: $13.86 vs. price of $9.16 (33.9% below fair value)
Industry Position: 66.3% below the Medical Diagnostics & Research median (#107 of 202)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
